160 related articles for article (PubMed ID: 9708626)
1. Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literature.
Safa AA; Reese DM; Carter DM; Phillipson J; Smith R; Dougherty S
Am J Clin Oncol; 1998 Aug; 21(4):323-6. PubMed ID: 9708626
[TBL] [Abstract][Full Text] [Related]
2. Tibia metastasis without prostate specific antigen (PSA) increase following radical vesiculo-prostatectomy.
Hübler J; Sükösd F; Czipri M
Int Urol Nephrol; 2000; 32(2):281-4. PubMed ID: 11229650
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
4. High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer.
Furuya Y; Cho S; Ohta S; Sato N; Kotake T; Masai M
J Urol; 2001 Jul; 166(1):213. PubMed ID: 11435864
[No Abstract] [Full Text] [Related]
5. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
Bruwer G; Heyns CF; Allen FJ
Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
[TBL] [Abstract][Full Text] [Related]
6. [Metastatic prostate cancer associated with low levels of prostate-specific antigen].
Diaz S; Salirrosas M
Rev Peru Med Exp Salud Publica; 2012; 29(4):541-4. PubMed ID: 23338642
[TBL] [Abstract][Full Text] [Related]
7. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
8. A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.
Iwamura H; Hatakeyama S; Tanaka Y; Tanaka T; Tokui N; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Ohyama C
BMC Res Notes; 2014 Jan; 7():64. PubMed ID: 24476098
[TBL] [Abstract][Full Text] [Related]
9. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
10. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
[TBL] [Abstract][Full Text] [Related]
11. Serum PSA and PAP measurements discriminating patients with prostate carcinoma from patients with nodular hyperplasia.
Shih WJ; Collins J; Mitchell B; Wierzbinski B
J Natl Med Assoc; 1994 Sep; 86(9):667-70. PubMed ID: 7525979
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Peripheral Vein Tumour Marker Levels, Internal Iliac Vein Tumour Marker Levels and Radical Prostatectomy Specimens in Patients with Prostate Cancer and Borderline High Prostate-Specific Antigen: A Pilot Study.
Farrelly C; Lal P; Trerotola SO; Nadolski GJ; Watts MM; Gorrian CM; Guzzo TJ
Cardiovasc Intervent Radiol; 2016 May; 39(5):724-731. PubMed ID: 26957011
[TBL] [Abstract][Full Text] [Related]
13. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
Drago JR; Badalament RA; Wientjes MG; Smith JJ; Nesbitt JA; York JP; Ashton JJ; Neff JC
Urology; 1989 Oct; 34(4):187-92. PubMed ID: 2477931
[TBL] [Abstract][Full Text] [Related]
14. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer metastatic to the external auditory canals.
Shrivastava V; Christensen R; Poggi MM
Clin Genitourin Cancer; 2007 Jun; 5(5):341-3. PubMed ID: 17645833
[TBL] [Abstract][Full Text] [Related]
16. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.
Rudoni M; Antonini G; Favro M; Baroli A; Brambilla M; Cardani G; Ciardi L; Sacchetti GM; Inglese E
Eur J Nucl Med; 1995 Mar; 22(3):207-11. PubMed ID: 7540551
[TBL] [Abstract][Full Text] [Related]
17. Metastatic prostatic adenocarcinoma in an inguinal hernia sac in a patient with undetectable serum prostate specific antigen level.
Chung SD; Yu HJ; Lin WC; Huang KH
J Formos Med Assoc; 2007 May; 106(5):397-9. PubMed ID: 17561475
[TBL] [Abstract][Full Text] [Related]
18. Recurrence of prostate adenocarcinoma presenting with multiple myeloma simulating skeletal metastases of prostate adenocarcinoma.
Huang E; Teh BS; Saleem A; Butler EB
Urology; 2002 Dec; 60(6):1111. PubMed ID: 12475684
[TBL] [Abstract][Full Text] [Related]
19. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
Choo R; Hruby G; Hong J; Hong E; DeBoer G; Danjoux C; Morton G; Klotz L; Bhak E; Flavin A
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):674-80. PubMed ID: 11849789
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
